检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:孙秀娣[1] 陈君泽[1] 范金虎[1] 陶德明[1] 郑素芳[1] 王华余[1] 刘新伏[1] 杜辉章[1] 邹小农[1] 刘彬[1] 乔友林[1]
机构地区:[1]中国医学科学院中国协和医科大学肿瘤研究所肿瘤医院,北京100021
出 处:《中国肿瘤》2005年第6期357-361,共5页China Cancer
基 金:国家重点医学科技攻关"八五"基金资助项目(85-914-01-02)
摘 要:[目的]探讨核黄素强化盐干预试验对人群肿瘤发病率的影响。[方法]对盐亭县核黄素强化盐干预试验人群干预期(1992~1996)和干预停止期(1997~2001)的肿瘤发病资料进行分析。[结果]试验组男性食管癌、肺癌、结直肠癌,女性食管癌、白血病、宫颈癌发病率在干预期高于对照组,而在干预停止期低于对照组。两组人群10年的肿瘤发病资料比较,试验组除胃癌外其他肿瘤发病率均低于对照组,尤其是食管癌和宫颈癌发病率明显低于对照组,而两组人群中肺癌、结直肠癌发病率都上升,但试验组的上升幅度低于对照组。[结论]试验组与对照组肿瘤发病率的差异,提示补充核黄素有利于降低肿瘤的发病风险,值得在更大范围的肿瘤高危人群中推广。Purpose] To investigate the effect on cancer incidence in Riboflavin Fortified Salt Intervention population. [Methods] The cancer incidence of the population with Riboflavin Fortified Salt Intervention during the intervention period (1992~1996) and the period after intervention (1997~2001) were analyzed.[Results]The incidence rates of esophageal cancer, lung cancer and colorectal cancer for male, esophageal cancer, leukemia and cervical cancer for female among the intervention population were higher than those in control group during the intervention period, while they were lower than that in control group during the period after intervention. Compared with control group, lower incidence rates of all the other cancers except for stomach cancer were observed among the trial group in the period after intervention, especially for esophageal cancer and cervical cancer. Although the increase incidence of lung cancer and colorectal cancer were observed between both groups. A less extent of increase was found among the trial group than that in control group. [Conclusion] The difference of incidence in trial group and control group suggests that supplement of riboflavin might decrease the cancer risk, it is worthy extending for a large scale of high risk population.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.229